Redeye endorses today’s news that Elicera has received an orphan drug designation in the US for ELC-...
Redeye comments on Iconovo’s collaboration with Lonza to develop a reformulated obesity treatment.
Redeye comments on Arise’s new SEK50m share repurchase program, refinancing its green facility of EU...
Redeye initiates coverage of OEM International, a niche acquirer of technology trading SMEs that has...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 10 januari 2025 att Bolaget har erhållit ty...
Henrik Andersson, who has served as CEO of Northbaze since 2018, has informed the board of directors...
Redeye makes minor revisions to estimates ahead of Enea’s Q4 2024 report due on 30 January 2025.
Redeye comments on SynAct’s successful rights issue.
Nexttobe, existing investor Ulf Landegren, certain board members, senior executives and guarantee co...
Redeye provides a comment on Xspray following yesterday's press release announcing a delay in the re...
Duell publishes its Q1/2025 (9/24-11/24) business review on 16th of January.
Redeye retains its Q4 and 2025 forecasts for Transtema.
Q4 report due 18 February We forecast net sales of SEK 189m, EBITA of SEK 27m Trading near low end o...
Redeye comments on Sivers Semiconductors’ announcement of a new USD5.
Redeye expects a stable Q4 report from Addnode, sharing a lot of similarities with Q3.
Redeye comments on the organisational changes and their implications on forecasts and makes a previe...
Eolus signs agreement to sell 100 MW battery storage project Estimated EV for the project in the USD...
Sells Ofir to Jobindex for DKK 20m, or ~DKK 1.0/share.
Mendus’s lead asset, vididencel, is fast approaching the pivotal stages of development in acute myel...
Smart Eye has announced an agreement to license iris recognition technology from Fingerprint Cards f...
